Research on the Inhibitory Effect of Doxorubicin-loaded Liposomes Targeting GFAP for Glioma Cells


Cite item

Full Text

Abstract

Background:Glioma is the most common and devastating brain tumor. In recent years, doxorubicin (DOX) is one of the drugs used in the treatment of gliomas, but it has side effects and poor clinical outcomes. Therefore, the delivery of drugs to the tumor site by targeted transport is a new approach to tumor treatment.

Objective:This study focuses on the anti-tumor effects of GFAP-modified drug-carrying liposomes loaded with DOX (GFAP-DOX-LPs) on gliomas.

Methods:GFAP-DOX-LPs were prepared by solvent evaporation method. After characterization analysis of GFAP-DOX-LPs, the encapsulation efficiency, the drug loading capacity and in vitro release performance were determined. Then, the MTT method was used to investigate the cytotoxicity and proliferative behavior of U251 and U87 cell lines. After that, flow cytometry was used to investigate the effect of the drug administration group on tumor cell apoptosis. Eventually, the anti-tumor activity was tested in vivo.

Results:The average particle size of GFAP-DOX-LPs was determined to be 116.3 ± 6.2 nm, and the average potential was displayed as 22.8 ± 7.2 mv. Besides, the morphology of the particle indicated a spherical shape. The encapsulation rate and drug loading were calculated and determined, which were 91.84 ± 0.41% and 9.27 ± 0.55%. In an acidic medium, the DOX release rate reached about 87%. GFAP-DOX-LPs could target glioma cells with low cytotoxicity and inhibit glioma cell proliferation with high efficiency, resulting in promoting apoptosis. The anti-tumor effect of GFAP-DOX-LPs was significantly enhanced. At the same time, the number of GFAPpositive cells in tumor tissues was significantly lower after treatment. Therefore, the overall survival time could be significantly prolonged.

Conclusion:The prepared GFAP-DOX-LPs had good targeting and glioma cell inhibition ability. This demonstrated the promising application of the prepared liposomes in tumor targeting, especially in the field of targeted drug delivery for the treatment of brain tumor.

About the authors

Qifeng Li

Department of Neurosurgery, Hangzhou Children's Hospital

Author for correspondence.
Email: info@benthamscience.net

Jiaming Xu

Department of Neurosurgery, Hangzhou Children's Hospital

Email: info@benthamscience.net

References

  1. Chen, X.; Guo, G.; Lu, Y.; Wang, S.; Zhang, Y.; Huang, Q. Mechanisms and functions of long non coding RNAs in glioma. Oncol. Rep., 2021, 45(4), 9. doi: 10.3892/or.2021.7960 PMID: 33649805
  2. Yang, Q.; Zhang, J.; Zhang, X.; Miao, L.; Zhang, W.; Jiang, Z.; Zhou, W. C-C motif chemokine ligand 2/C-C receptor 2 is associated with glioma recurrence and poor survival. Exp. Ther. Med., 2021, 21(6), 564-564. doi: 10.3892/etm.2021.9996 PMID: 33850536
  3. Oishi, T.; Koizumi, S.; Kurozumi, K. Molecular mechanisms and clinical challenges of glioma invasion. Brain Sci., 2022, 12(2), 291-291. doi: 10.3390/brainsci12020291 PMID: 35204054
  4. Nie, W.; Zan, X.; Yu, T.; Ran, M.; Hong, Z.; He, Y.; Yang, T.; Ju, Y.; Gao, X. Synergetic therapy of glioma mediated by a dual delivery system loading α-mangostin and doxorubicin through cell cycle arrest and apoptotic pathways. Cell Death Dis., 2020, 11(10), 928. doi: 10.1038/s41419-020-03133-1 PMID: 33116114
  5. Niu, W.; Xiao, Q.; Wang, X.; Zhu, J.; Li, J.; Liang, X.; Peng, Y.; Wu, C.; Lu, R.; Pan, Y.; Luo, J.; Zhong, X.; He, H.; Rong, Z.; Fan, J.B.; Wang, Y. A biomimetic drug delivery system by integrating grapefruit extracellular vesicles and doxorubicin-loaded heparin-based nanoparticles for glioma therapy. Nano Lett., 2021, 21(3), 1484-1492. doi: 10.1021/acs.nanolett.0c04753 PMID: 33475372
  6. Adam, C.; Bray, T.L.; Pérez-López, A.M.; Tan, E.H.; Rubio-Ruiz, B.; Baillache, D.J.; Houston, D.R.; Salji, M.J.; Leung, H.Y.; Unciti-Broceta, A.A. 5-FU precursor designed to evade anabolic and catabolic drug pathways and activated by pd chemistry in vitro and in vivo. J. Med. Chem., 2022, 65(1), 552-561. doi: 10.1021/acs.jmedchem.1c01733 PMID: 34979089
  7. Zhang, H; Yamaguchi, T; Kawabata, K In vitro blood–brain barrier model derived from human iPS cells and its applications. Recent Adv. iPSC Technol, 2021, 5, 63-85.
  8. Fabel, K.; Dietrich, J.; Hau, P.; Wismeth, C.; Winner, B.; Przywara, S.; Steinbrecher, A.; Ullrich, W.; Bogdahn, U. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer, 2001, 92(7), 1936-1942. doi: 10.1002/1097-0142(20011001)92:73.0.CO;2-H PMID: 11745268
  9. Zhang, M.; Lou, C.; Cao, A. Progresses on active targeting liposome drug delivery systems for tumor therapy. Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih, 2022, 39(3), 633-638. PMID: 35788534
  10. Zhao, Y.Q.; Li, L.J.; Zhou, E.F.; Wang, J-Y.; Wang, Y.; Guo, L-M.; Zhang, X-X. Lipid-based nanocarrier systems for drug delivery: Advances and applications. Pharm. Fronts, 2022, 4(2), e43-e60. doi: 10.1055/s-0042-1751036
  11. Chopra, S.; Venkatesan, N.; Betageri, G.V. Liposomes as nanocarriers for anti-HIV therapy. Drug Deliv. Transl. Res., 2013, 3(5), 471-478. doi: 10.1007/s13346-013-0134-2 PMID: 25788354
  12. Alrbyawi, H.; Poudel, I.; Annaji, M.; Arnold, R.D.; Tiwari, A.K.; Babu, R.J. Recent advancements of stimuli-responsive targeted liposomal formulations for cancer drug delivery. Pharm. Nanotechnol., 2022, 10(1), 3-23. doi: 10.2174/2211738510666220214102626 PMID: 35156590
  13. Maruyama, M.; Tojo, H.; Toi, K.; Ienaka, Y.; Hyodo, K.; Kikuchi, H.; Ogawara, K.; Higaki, K. Effect of doxorubicin release rate from polyethylene glycol-modified liposome on anti-tumor activity in B16-BL6 tumor-bearing mice. J. Pharm. Sci., 2022, 111(2), 293-297. doi: 10.1016/j.xphs.2021.11.020 PMID: 34861247
  14. Minamisakamoto, T.; Nishiguchi, S.; Hashimoto, K.; Ogawara, K.; Maruyama, M.; Higaki, K. Sequential administration of PEG-Span 80 niosome enhances anti-tumor effect of doxorubicin-containing PEG liposome. Eur. J. Pharm. Biopharm., 2021, 169, 20-28. doi: 10.1016/j.ejpb.2021.08.013 PMID: 34461216
  15. Huang, X.; Chen, L.; Zhang, Y.; Zhou, S.; Cai, H.H.; Li, T.; Jin, H.; Cai, J.; Zhou, H.; Pi, J. GE11 peptide conjugated liposomes for EGFR-Targeted and chemophotothermal combined anticancer therapy. Bioinorg. Chem. Appl., 2021, 2021(31), 1-15. doi: 10.1155/2021/5534870 PMID: 33868396
  16. Bodegraven, E.J.; Sluijs, J.A.; Tan, A.K.; Robe, P.A.J.T.; Hol, E.M. New GFAP splice isoform (GFAPµ) differentially expressed in glioma translates into 21 kDa N‐terminal GFAP protein. FASEB J., 2021, 35(3), e21389-e21389. doi: 10.1096/fj.202001767R PMID: 33583081
  17. Chekhonin, V.P.; Baklaushev, V.P.; Yusubalieva, G.M.; Belorusova, A.E.; Gulyaev, M.V.; Tsitrin, E.B.; Grinenko, N.F.; Gurina, O.I.; Pirogov, Y.A. Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43. Nanomedicine, 2012, 8(1), 63-70. doi: 10.1016/j.nano.2011.05.011 PMID: 21703991
  18. Pan, B.; Li, P.; Chen, J.; Sun, J.; Huang, N. Study on the effect and mechanism of paclitaxel-succinic acid drug-loaded nanofibers in treating lung cancer. J. Nanosci. Nanotechnol., 2021, 21(2), 909-913. doi: 10.1166/jnn.2021.18649 PMID: 33183423
  19. Sun, W.; Chen, G.; Du, F.; Li, X. Targeted drug delivery to cancer stem cells through nanotechnological approaches. Curr. Stem Cell Res. Ther., 2021, 16(4), 367-384. doi: 10.2174/1574888X15999201001204727 PMID: 33023455
  20. Sonker, M.; Bajpai, S.; Khan, M.A.; Yu, X.; Tiwary, S.K.; Shreyash, N. Review of recent advances and their improvement in the effectiveness of hydrogel-based targeted drug delivery: A hope for treating cancer. ACS Appl. Bio Mater., 2021, 4(12), 8080-8109. doi: 10.1021/acsabm.1c00857 PMID: 35005919
  21. Meng, L.; Wang, C.; Lu, Y.; Sheng, G.; Yang, L.; Wu, Z.; Xu, H.; Han, C.; Lu, Y.; Han, F. Targeted regulation of blood–brain barrier for enhanced therapeutic efficiency of hypoxia-modifier nanoparticles and immune checkpoint blockade antibodies for glioblastoma. ACS Appl. Mater. Interfaces, 2021, 13(10), 11657-11671. doi: 10.1021/acsami.1c00347 PMID: 33684289
  22. Vatutin, M.T.; Sklyannaya, E.V.; El-Khatib, M.A. Hepatotoxicity of chemotherapeutic agents. Curr. State Problem, 2016, 21(6), 325-333.
  23. Shivapriya, G.; Bhagavathy, S. Formulation, characterization and in vitro drug delivery of vitexin loaded liposomes. Int. J. Pharm. Sci. Technol., 2021, 16(6), 637-644.
  24. Singh, A.; Srivastava, A.; Gupta, A. Liposomal drug delivery system – a review. J. Appl. Pharm. Sci. Res., 2020, 3(3), 07-10. doi: 10.31069/japsr.v3i3.2
  25. Gorbik, V.S.; Shprakh, Z.S.; Kozlova, Z.M.; Salova, V.G. Liposomes as a targeted delivery system of drugs. Russian J. Biother., 2021, 20(1), 33-41. doi: 10.17650/1726-9784-2021-20-1-33-41
  26. Yan, H.; Wei, P.; Song, J.; Jia, X.; Zhang, Z. Enhanced anticancer activity in vitro and in vivo of luteolin incorporated into long-circulating micelles based on DSPE-PEG2000 and TPGS. J. Pharm. Pharmacol., 2016, 68(10), 1290-1298. doi: 10.1111/jphp.12598 PMID: 27465923
  27. Zhang, J.; He, Y.; Jiang, J.; Li, M.; Jin, C.; Wang, L.; Wang, D. In vitro and in vivo evaluation of folate-mediated PEGylated nanostructured lipid carriers for the efficient delivery of furanodiene. Drug Dev. Ind. Pharm., 2017, 43(10), 1610-1618. doi: 10.1080/03639045.2017.1328429 PMID: 28481661
  28. Feng, L.; Saulsbury, M.; Heyliger, S. Abstract 5538: A pH-responsive doxorubicin-lipid conjugate loaded nanomedicine for breast cancer treatment. Cancer Res., 2015, 75(15), 5538-5538.
  29. Fang, C.; Shi, B.; Pei, Y. Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-α-loaded nanoparticles1. Acta Pharmacol. Sin., 2005, 26(2), 242-249. doi: 10.1111/j.1745-7254.2005.00537.x PMID: 15663906
  30. Sokolova, V.; Nzou, G.; van der Meer, S.B.; Ruks, T.; Heggen, M.; Loza, K.; Hagemann, N.; Murke, F.; Giebel, B.; Hermann, D.M.; Atala, A.J.; Epple, M. Ultrasmall gold nanoparticles (2 nm) can penetrate and enter cell nuclei in an in vitro 3D brain spheroid model. Acta Biomater., 2020, 111(15), 349-362. doi: 10.1016/j.actbio.2020.04.023 PMID: 32413579
  31. Grossi, C.; Guccione, C.; Isacchi, B.; Bergonzi, M.C.; Luccarini, I.; Casamenti, F.; Bilia, A.R. Development of blood-brain barrier permeable nanoparticles as potential carriers for salvianolic acid B to CNS. Planta Med., 2017, 83(5), 382-391. PMID: 27002395
  32. Sydow, K.; Nikolenko, H.; Lorenz, D.; Müller, R.H.; Dathe, M. Lipopeptide-based micellar and liposomal carriers: Influence of surface charge and particle size on cellular uptake into blood brain barrier cells. Eur. J. Pharm. Biopharm., 2016, 109, 130-139. doi: 10.1016/j.ejpb.2016.09.019 PMID: 27702684
  33. Simón-Vázquez, R.; Tsapis, N.; Lorscheider, M.; Rodríguez, A.; Calleja, P.; Mousnier, L.; de Miguel Villegas, E.; González-Fernández, Á.; Fattal, E. Improving dexamethasone drug loading and efficacy in treating arthritis through a lipophilic prodrug entrapped into PLGA-PEG nanoparticles. Drug Deliv. Transl. Res., 2022, 12(5), 1270-1284. doi: 10.1007/s13346-021-01112-3 PMID: 34993924
  34. Cheng, Q.F.; Qian, H.Q.; Zhang, D.H.; Huang, Y.; Sha, H.Z.; Liu, B.R. Evaluation for preparation and anticancer efficacy in vitro of drug-loaded nanoerythrosomes. Zhongguo Zhongyao Zazhi, 2016, 41(11), 2093-2097. PMID: 28901106
  35. Wu, Q.; Liu, D.; Zhang, X.; Wang, D. DongYe, M.; Chen, W.; Lin, D.; Zhu, F.; Chen, W.; Lin, H. Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection. Drug Deliv., 2019, 26(1), 290-299. doi: 10.1080/10717544.2019.1582728 PMID: 30895841
  36. Zhao, X.; Li, J.; Cheng, S.; Li, S.; Bai, X.; Xi, J. Study on the role of paclitaxel nano-drug delivery system in inhibiting intimal hyperplasia and improving vascular remodeling in abdominal aortic injury model. J. Nanosci. Nanotechnol., 2021, 21(2), 1385-1389. doi: 10.1166/jnn.2021.18653 PMID: 33183488
  37. Di Gregorio, E.; Romiti, C.; Di Lorenzo, A.; Cavallo, F.; Ferrauto, G.; Conti, L. RGD_PLGA nanoparticles with docetaxel: A route for improving drug efficiency and reducing toxicity in breast cancer treatment. Cancers, 2022, 15(1), 8. doi: 10.3390/cancers15010008 PMID: 36612006

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers